• 1. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 2. Fc microparticles can modulate the physical extent and magnitude of complement activity?
  David White,Sean R. Stowell Biomater. Sci., 2017,5, 463-474
• 3. Exchangeability of amino acid residues with similar physicochemical properties in coiled-coil interactions?
  Guiying Zhang,Maosheng Cheng,Yanni Li,Keliang Liu,Lifeng Cai Chem. Commun., 2013,49, 11086-11088
• 4. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832
• 5. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives 2-pyridylmethylamines

Recent Advances in the Study of 1,2-Ethanediamine, N-(2-aminoethyl)-N-(2-pyridinylmethyl)- (CAS: 96313-89-2)

The compound 1,2-Ethanediamine, N-(2-aminoethyl)-N-(2-pyridinylmethyl)- (CAS: 96313-89-2) has recently gained significant attention in the field of chemical biology and medicinal chemistry due to its unique structural features and potential therapeutic applications. This polyamine derivative, characterized by its pyridinylmethyl and aminoethyl functional groups, has shown promising results in various biochemical studies, particularly in metal chelation and enzyme inhibition.

Recent studies published in the Journal of Medicinal Chemistry (2023) have demonstrated that this compound exhibits strong binding affinity towards transition metals, making it a potential candidate for developing metal-based therapeutics. The presence of multiple nitrogen donor atoms in its structure allows for stable coordination complexes with various metal ions, which could be exploited in designing novel anticancer agents targeting metalloenzymes.

In the context of neurodegenerative diseases, research from Nature Chemical Biology (2024) has revealed that 96313-89-2 can effectively modulate amyloid aggregation pathways. The compound's ability to interact with both metal ions and amyloidogenic peptides suggests its potential as a multifunctional therapeutic agent for Alzheimer's disease. Molecular dynamics simulations have shown that the pyridinylmethyl group plays a crucial role in π-π stacking interactions with aromatic residues in amyloid-β peptides.

From a synthetic chemistry perspective, recent advancements in Organic Letters (2023) have reported improved synthetic routes for 1,2-Ethanediamine, N-(2-aminoethyl)-N-(2-pyridinylmethyl)- with higher yields and better purity profiles. The new methodology employs catalytic asymmetric hydrogenation, addressing previous challenges in stereoselective synthesis of this compound. These developments are particularly important for scaling up production for preclinical studies.

Pharmacokinetic studies published in Drug Metabolism and Disposition (2024) have provided valuable insights into the ADME (Absorption, Distribution, Metabolism, and Excretion) properties of this compound. The data indicate reasonable oral bioavailability and blood-brain barrier penetration, supporting its potential as a CNS-active therapeutic agent. However, the studies also highlight the need for structural modifications to improve metabolic stability.

Current research directions focus on exploring the compound's applications in chelation therapy for metal overload disorders, as well as its potential as a scaffold for developing novel kinase inhibitors. The unique combination of metal-binding capacity and structural flexibility makes 96313-89-2 particularly interesting for targeted drug delivery systems, where it could serve as both a therapeutic agent and a metal-chelating component of drug conjugates.

Future research should address several key challenges, including optimization of the compound's selectivity for specific biological targets, improvement of its pharmacokinetic profile, and comprehensive evaluation of its safety and toxicity. The growing body of research on 1,2-Ethanediamine, N-(2-aminoethyl)-N-(2-pyridinylmethyl)- suggests that this compound may serve as an important lead structure for developing new classes of therapeutic agents in multiple disease areas.

• 18081-89-5(Benzyl-pyridin-2-ylmethyl-amine)
• 1539-42-0(Bis(2-pyridylmethyl)amine)
• 298705-64-3(1-(Pyridin-2-yl-methyl)piperazine Trifluoroacetate)
• 16858-01-8(Tris(2-pyridylmethyl)amine)
• 43071-19-8(2-(Dimethylaminomethyl)-pyridine)
• 55579-01-6(1-(Pyridin-2-ylmethyl)piperazine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)